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PURPOSE. Although primary congenital glaucoma (PCG)–associ-
ated CYP1B1 mutations in the heterozygous state have been
evaluated for association with primary open-angle glaucoma
(POAG) in several small studies, their contribution to the oc-
currence of POAG is still controversial. The present study was
conducted to determine whether heterozygous functionally
characterized CYP1B1 mutations are associated with the dis-
ease in a large cohort of German patients with POAG.
METHODS. The frequency of CYP1B1 variants on direct se-
quencing of the entire coding region was compared in 399
unrelated German patients with POAG (270, POAG; 47, JOAG;
and 82, NTG) and 376 control subjects without any signs of
glaucoma on ophthalmic examination. In vitro functional as-
says were performed and relative enzymatic activity of the
CYP1B1 variants embedded in their respective background
haplotypes and not previously unambiguously classified were
determined, to assess their possible causative role.
RESULTS. Apart from known polymorphic variants, 11 amino
acid substitutions in CYP1B1 reported before, both in PCG and
POAG cases, were identified. After in vitro functional assay,
variants P52L and R368H showed marked reduction of activity,
confirming their role as loss-of-function mutations similar to
previously determined variants G61E, N203S, and G329V. In
contrast, variants G168D, A443G, and A465V showed no rele-
vant effects and were thus classified as polymorphisms. Over-
all, seven functionally impaired variants were present in 13
(3.6%) patients and in 1 (0.2%) control subject (P  0.002,
OR  5.4). Reanalysis of previous studies reporting CYP1B1
mutations in patients with POAG based on updated functional
validation showed a significant excess of carriers among pa-
tients compared to controls (OR  3.85; P  2.3  107).
CONCLUSIONS. Heterozygous CYP1B1 mutations with absent or
reduced relative enzymatic activity can be considered a risk
factor for POAG. (Invest Ophthalmol Vis Sci. 2010;51:
249–254) DOI:10.1167/iovs.09-3880
Glaucoma represents a heterogeneous group of complexneurodegenerative diseases and is the second leading
cause of blindness worldwide.1,2 The most common form of
glaucoma is primary open-angle glaucoma (POAG; OMIM
137760) which affects more than 35 million people world-
wide.3,4 POAG is characterized by loss of retinal ganglion cells,
specific atrophy of the optic nerve, progressive loss of the
neuroretinal rim of the optic disc, with corresponding progres-
sive visual field loss, and, if untreated, eventual blindness.2
Elevated IOP appears to be a major risk factor, although glau-
coma develops in some patients even in the absence of ele-
vated IOP.5 In this case, glaucoma is defined as normal-tension
glaucoma (NTG). Based on age at onset, a juvenile form (JOAG,
age at onset before 40 years) is differentiated from adult-onset
POAG.6 A family history of the disease has long been recog-
nized as a risk factor, suggesting that specific genetic variants
contribute to pathogenesis of POAG. In some families, glau-
coma segregates as a Mendelian trait with reduced penetrance
and variable expressivity, but most cases are sporadic, suggest-
ing a multifactorial contribution to its etiology.7
To date, 14 genetic loci for POAG have been identified
through linkage studies (GLC1A–GLC1N). However, only three
causative genes have been described: myocilin (MYOC/
GLC1A), optineurin (OPTN/GLC1E), and WD repeat domain 36
(WDR36/GLC1G). Altogether, mutations in these genes ac-
count for less than 10% of POAG cases.8 In addition, associa-
tion studies have implicated more than 20 other genes.9 Al-
though most of these have been reported in single studies, a
few have been investigated in multiple-association studies, but
findings have been inconsistent. One of these POAG-associated
genes is cytochrome P450 1B1 (CYP1B1: MIM 601771 (Men-
delian Inheritance in Man; National Center for Biotechnology
Information, Bethesda, MD). Cytochrome P450 proteins are
monooxygenases, which catalyze many reactions involved in
the metabolism of drugs as well as steroids and other lipids.10
Mutations in CYP1B1 are the predominant cause of primary
congenital glaucoma (PCG), which although generally rare, is
the most common form of glaucoma in infants, with more than
80% of cases observed within the first year of life.11 This
disorder is most likely due to developmental defects in the
trabecular meshwork and the anterior chamber angle. In PCG,
elevated IOP can rapidly lead to axonal loss and permanent loss
of vision in untreated individuals. Inheritance is primarily au-
tosomal recessive with variable penetrance.12 Although the
role of CYP1B1 in congenital glaucoma is not well understood,
the enzyme is probably responsible for the metabolism of
compounds that are critical for the developing eye.10
From the 1Institute of Human Genetics and the 2Department of
Ophthalmology; Friedrich-Alexander-University Erlangen-Nuremberg,
Erlangen, Germany; the 3Section of Pharmacogenetics, Department of
Physiology and Pharmacology, Karolinska Institutet, Stockholm, Swe-
den; and the 4Institute of Human Genetics, University Regensburg,
Regensburg, Germany.
5Present affiliation: MGZ-Medical Genetics Centre, Munich, Ger-
many.
Supported by Grants SFB 539 and in part by Grant WE1259/14-3
from the German Research Foundation (DFG).
Submitted for publication April 20, 2009; revised June 22, 2009;
accepted July 17, 2009.
Disclosure: F. Pasutto, None; G. Chavarria-Soley, None; C.Y.
Mardin, None; K. Michels-Rautenstrauss, None; M. Ingelman-
Sundberg, None; L. Ferna´ndez-Martínez, None; B.H.F. Weber,
None; B. Rautenstrauss, None; A. Reis, None
Corresponding author: Andre´ Reis, Institute of Human Genetics,
Friedrich-Alexander-University Erlangen-Nuremberg, Schwabachanlage
10, 91054 Erlangen, Germany; reis@humgenet.uni-erlangen.de.
Glaucoma
Investigative Ophthalmology & Visual Science, January 2010, Vol. 51, No. 1
Copyright © Association for Research in Vision and Ophthalmology 249
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933452/ on 07/05/2017
Initially, CYP1B1 was suggested to be a modifier gene for
the expression of MYOC in patients with JOAG.13 However,
some studies have indicated that CYP1B1 may play a causative
role in JOAG, with possible monogenic association in
French,14 Indian,15 and Spanish16 patients. Furthermore, het-
erozygous variants in CYP1B1 have been proposed as potential
factors governing severity in patients with POAG.17 In all these
reports, however, heterozygous CYP1B1 variants have also
been found in healthy subjects, which raises questions about
their role as disease-causing mutations.
In a recent study, we reported a measurement method for
relative enzymatic activity (combining net enzymatic activity
and protein abundance) and found variation in activity be-
tween the major CYP1B1 haplotypes as well as either a drastic
or an intermediate to mild reduction in activity of four different
CYP1B1 mutations (G61E, Y81N, N203S, and E229K), com-
pared with that of the corresponding background haplotype.18
A marked decrease of the relative activity was seen for variants
N203S and G61E, which were classified as bona fide mutations.
In contrast, variants Y81N showed an intermediate and E229K
a mild reduction in activity, thus leading to a classification as
hypomorphic alleles.18,19
In the present study, we evaluated whether heterozygous
CYP1B1 mutations showing absent or reduced relative enzy-
matic activity are associated with the disease in a large cohort
of German patients with POAG.
MATERIALS AND METHODS
Patients and Control Subjects
The study was approved by the ethics review board of the Medical
Faculty of the University of Erlangen-Nuremberg and was conducted in
accordance with the tenets of the Declaration of Helsinki. All subjects
gave informed consent before entering the study.
The group of patients with glaucoma consisted of 399 subjects of
German (European) origin. Two hundred seventy had POAG (high-
pressure POAG), 47 had JOAG, and 82 had open-angle NTG. All
individuals underwent standardized clinical examinations for glaucoma
at the Ophthalmology Department of the University of Erlangen-
Nuremberg. These comprised slit lamp biomicroscopy, gonioscopy,
automated visual field testing (model G1; Octopus, Interzeag, Switzer-
land), fundus photography (fundus camera; Carl Zeiss Meditec, Jena,
Germany), optional laser scanning tomography (HRT I and II; Heidel-
berg Engineering, Heidelberg, Germany) of the disc, and a 24-hour
Goldmann applanation IOP tonometry profile with five measurements.
Manifest high-tension POAG was defined as the presence of glaucoma-
tous optic disc damage (in at least one eye), visual field defects in at
least one eye and IOP higher than 21 mm Hg in one eye without
therapy. According to Jonas et al.20 a stage 0 optic disc is defined as
normal, stage I as having vertical elongation of the cup and neuroreti-
nal rim loss at the 12- and 6-o’clock positions, stage II as showing focal
rim loss, stage III and IV has having advanced rim loss, and stage V as
absolute optic disc atrophy.21 Disc area was measured with HRT or
estimated with Goldmann lens and slit lamp (Haag-Streit, Ko¨niz, Swit-
zerland). A pathologic visual field was defined by a pathologic Bebie
curve: three adjacent test points with more than 5-dB sensitivity loss or
at least one point with more than a 15-dB loss.
Persons with secondary glaucoma caused by such disorders as
primary melanin dispersion, pseudoexfoliation, or uveitis or by previ-
ously raised IOP after trauma or a period of steroid administration were
excluded. Glaucomatous optic nerve damage was defined as focal/
diffuse loss of neuroretinal rim or nerve fiber layer associated with a
specific visual field defect. Patients who showed glaucomatous
changes of the optic disc and visual field, but no IOP elevation over 21
mm Hg after 24 hours of IOP measurement (sitting and supine body
position) without therapy, received a diagnosis of NTG. In addition, in
the patients with NTG, a neurologic examination was performed to
exclude an intracerebral expansion or malperfusion. Stenosis of the
aorta carotis interna was excluded by means of sonography. Patients
were classified as having JOAG when age at onset in the index case was
below 40 years and no other ocular reason for open-angle glaucoma
was identifiable. At the time of examination, the ages of the patients
ranged from 14 to 96 years with a mean of 66.9  13.4. In total 178
(44.4%) patients had a family history of glaucoma.
The 376 control subjects were all of German origin and recruited
from the same geographic regions as the patients. In addition, control
subjects underwent ophthalmic examination and were age and sex
matched. Thus, at the time of examination and inclusion in this study
the ages ranged from 51 to 92 years with a mean of 73.9  6.4. They
had IOP below 20 mm Hg, no glaucomatous disc damage, and no
family history of glaucoma. Visual acuity was at least 0.8 or 20/25 and
the media were clear for examination.
All patients were screened for the myocilin (MYOC), optineurin
(OPTN) (data not shown), and WD repeat domain 36 (WDR36)22
mutations, as determined by direct sequencing of all coding regions.
Mutation Screening
Genomic DNA was prepared from peripheral blood samples by a
standard salting-out protocol. Individual coding exons of the CYP1B1
gene, including flanking intronic/UTR sequences were amplified by
polymerase chain reaction (PCR) with appropriate amplification pro-
tocols. Primer sequences were selected using Primer3 software and are
available on request. Purified PCR fragments were sequenced with big
dye termination chemistry (ver. 3.1; Applied Biosystems, Inc., [ABI],
Weiterstadt, Germany) on a capillary automated sequencer (3730 Ge-
netic Analyzer; ABI). Each variant was confirmed by a second indepen-
dent analysis. GenBank for CYP1B1 accession NM_022184 was used as
cDNA reference sequence and NT_000104 as genomic reference se-
quence. We used Q16678 (CYP1B1_HUMAN), from the Swiss-Prot/
TrEMBL Database as reference protein sequences. URLs of all data
sources are provided in the Appendix.
Plasmids Expression
Based on wild-type human CYP1B1 cDNA cloned into the pYeDP60
expression plasmid23 various CYP1B1 constructs were generated by
site-directed mutagenesis (QuikChange Site-Directed Mutagenesis Kit;
Stratagene, La Jolla, CA) according to the instructions of the manufac-
turer. Several rounds of site-directed mutagenesis were needed to
establish the different SNP haplotypes and the variants embedded in
their original haplotype (for more details please refer to Ref. 32).
All plasmids were sequenced using the dye-termination cycle se-
quencing kit (Prism Big Dye; ABI) and analyzed (Genetic Analyzer
3730; ABI) to ensure that the constructs were correct.
Expression of Human CYP1B1 Variants in Yeast
The different human CYP1B1 variants were coexpressed with human
reductase in a Saccharomyces cerevisiae strain, INVSc1-HR MAT
his31 leu2 trp1–289 ura3–52 (pFL-35 human reductase). Yeast cells
were transfected with the pYeDP60-CYP1B1 expression plasmids. Sin-
gle colonies were inoculated into selective medium (lacking uracil) and
grown, followed by microsome isolation according to a previously
established protocol.24 Microsomes were stored at 80°C until use.
Microsomal protein concentration and total P450 content were deter-
mined with previously described methods.25,26 The p450 content is
essentially accounted for by the overexpressed CYP1B1.
Determination of Enzymatic Activity
CYP1B1 activity in microsome extracts was quantified (P450-Glo
CYP1B1 Assay Kit; Promega, Madison, WI) according to the instruc-
tions of the manufacturer. To measure enzymatic activity, 1 picomole
of each CYP1B1 variant was incubated with a luminogenic substrate
and NADPH regeneration system. As a result, a luciferin product
(D-luciferin) was generated, and luminescence (proportional to cyto-
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chrome P450 activity) was measured on a microplate reader (GENios;
Tecan, Maennedorf, Switzerland). The assays were performed in trip-
licate for all variants, original background haplotypes, and the negative
control (microsomal extract from yeast transformed with the empty
vector). The luminescence values for the negative control were sub-
tracted from values of the rest of the samples. The mutants were
compared against the corresponding background haplotype.
Statistical comparisons were performed with a one-way ANOVA,
followed by the least-significant difference (LSD) test (for more details
please refer to Ref. 18).
Statistical Analysis
Probabilities were calculated with Fisher’s exact test; P  0.05 was
considered statistically significant. Odds ratio (OR) and 95% confi-
dence interval (CI) were calculated with the free available software
written by David J. R. Hutchon.
RESULTS
An extensive screening for mutations using direct sequencing
of the complete coding sequence of CYP1B1, including un-
translated 5, 3, and intronic flanking regions was performed
on a well-studied, previously characterized cohort of 399 un-
related patients with glaucoma (270 with POAG, 47 with
JOAG, and 82 with NTG) and 376 healthy subjects of German
(European) origin.22 Apart from known polymorphic variants,
this systematic mutation screen led to the identification of 11
amino acid substitutions in CYP1B1 (Table 1). These 11 vari-
ants have been reported before, both in PCG and POAG cases,
and some of them have also been found in healthy sub-
jects.27,28 To delineate variants impairing enzymatic function,
we performed in vitro functional assays for CYP1B1 amino acid
changes, P52L, G168D, R368H, A443G, and V465A not previ-
ously unambiguously classified. These variants were generated
in vitro by site-directed mutagenesis, embedded in their respec-
tive background haplotypes. The relative enzymatic activity of
each variant was calculated by multiplying its molar enzymatic
activity and relative enzyme amount.18 Variants P52L and
R368H presented a drastic decrease in relative enzymatic ac-
tivity (Fig. 1), confirming their role as loss-of-function muta-
tions similar to the previously reported variants G61E,
N203S,18 and G329V.29 In contrast, relative enzymatic activity
of the variants G168D, A443G, and V465A was unchanged or
even slightly increased in respect to that of their respective
haplotypes, but within the normal range seen in wild-type
haplotypes resulting in a classification as polymorphisms.
In total we saw six bona fide mutations (P52L, W57X, G61E,
R368H, N203S, and G329V) in seven patients, but none in
control individuals. In addition, we found two variants previ-
ously classified as hypomorphic. The more severely impaired
variant Y81N was present in six patients compared with one
TABLE 1. Identified CYP1B1 Mutations and Polymorphisms
Exon
Nucletotide
Change
Amino Acid
Change
Patients
(n  399)
Controls
(n  376) Functional Classification
E2 c.155CT Pro52Leu 1 0 Mutation
E2 c.171GA Trp57X 1 0 Mutation
E2 c.182GA Gly61Glu 1 0 Mutation
E2 c.241TA Tyr81Asn 6 1 Hypomorphic allele
E2 c.608AG Asn203Ser 1 0 Mutation
E2 c.986GT Gly329Val 1 0 Mutation
E3 c.367GA Arg368His 2 0 Mutation
E2 c.503GA Gly168Asp 1 0 Polymorphism
E2 c.685GA Glu229Lys 8 10 Polymorphism
E3 c.1328GC Ala443Gly 1 1 Polymorphism
E3 c.1394TC Val465Ala 1 0 Polymorphism
FIGURE 1. Molar enzymatic activity, relative CYP1B1 abundance and
relative CYP1B1 activity. (A) Molar enzymatic activity of mutations. (B)
Relative CYP1B1 abundance of the mutations. (C) Relative CYP1B1
activity of the mutations. Different column shades correspond to the
different background haplotypes. Statistical comparison was per-
formed with a one-way ANOVA, followed by the LSD test. The mutants
were compared against the corresponding background haplotype. *Sig-
nificant at the 5% level.
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healthy subject, suggesting that it may represent a risk factor
for POAG. The milder E229K was found in similar frequency in
patients and controls (2% and 3%, respectively) suggesting it
should be reclassified as a polymorphism (Table 1). This result
is in line with the observation of evolutionary conservation
of position Y81 but not of E229 throughout orthologues
and paralogues in different mammalian species, as previous
reported.16
When Y81N was included, we saw a variant with impaired
function in a total of 13 patients (3.6%) but only 1 healthy
subject (0.2%). Thus, the CYP1B1 mutation rate in POAG
patients is significantly increased over that expected (P 
0.0018, Fisher’s exact test; OR  5.4, 95% CI  1.9–15.5). In
fact, considering a prevalence of 2.85  105 of PCG in
Western countries, the expected frequency of heterozygosity
in the normal population under Hardy-Weinberg equilibrium is
approximately 1%, assuming a recessive mode of inheritance.30
The mutation-positive patient group comprised both juve-
nile- and adult-onset POAG, with age at diagnosis varying from
6 to 74 years (Table 2). Ten patients had elevated (maximum)
IOP ranging from 24 to 46 mm Hg, whereas three had IOP
measurements in the normal range: 19 and 21 mm Hg, respec-
tively. Among the 13 patients, 3 carried an MYOC mutation,
but none presented with a WDR36 or OPTN mutation (Table
2). Confirming a previous report,13 we also observed that
patients carrying both CYP1B1 and MYOC mutations pre-
sented with a relatively early manifestation of the disease. This
finding was also true, however, in those patients carrying only
CYP1B1 mutations with markedly reduced relative enzymatic
activity—for example, P52L and N203S. One patient with
POAG was found to be compound heterozygous for two
CYP1B1 mutations: the bona fide mutation G61E and the
hypomorphic allele Y81N.
We next reanalyzed the CYP1B1 variants reported in pre-
vious studies14–16,28,31 based on recently published functional
tests and those described in this study18,19,29,32,33 and reclas-
sified them into either functionally impaired, polymorphism,
or undetermined (Table 3). In line with our results, we ob-
served a significant excess of patients carrying CYP1B1 muta-
tions in the combined group as well as in each study (com-
bined OR  3.85, 95% CI  2.21–6.70; P  2.3  107;
two-tailed Fisher’s exact test).
DISCUSSION
Different CYP1B1 heterozygous variants have been implicated
as a risk factor for POAG in studies of different population
groups.14,16,28,31 Moreover, in all these studies, it has been
seen that the frequency of the mutations, their nature, and
their diversity vary greatly with the population studied. This
fact combined with the relatively small groups of patients
available, and the unknown role of the variants detected had
made it difficult to clearly show the association of CYP1B1
with disease.
In comparison, our work first includes a large number of
patients and control subjects, thus providing a stronger power
for the association analysis and second assesses the functional
TABLE 2. Clinical Features of Patients with Functionally Impaired CYP1B1 Mutations
Subject ID
CYP1B1
Variant
MYOC
Variant Phenotype
Age at
Diagnosis
(y)
MAX IOP
(mmHg; R/L)
Optic Disc
(Jonas)
Disc Area
(mm2)
20315 P52L — JOAG 6 30/30 ND ND
99052 W57X G367R JOAG 22 46/38 V/III 2.85/2.89
10927 G61E/Y81N — POAG 46 43/28 IV/IV ND
18513 Y81N — POAG 74 28/21 ND 2.1/2.1
99184 Y81N — NTG 69 21/21 II/II 2.49/2.48
17725 Y81N — POAG 54 29/26 ND 2.79/2.97
99004 Y81N P370L JOAG 7 30/33 IV/V ND
99299 Y81N — NTG 60 19/19 III/III 2.8/2.8
99590 Y81N — POAG 51 24/24 IV/V 2.7/2.0
99168 N203S E368X JOAG 39 38/38 ND 1.99/1.87
17687 G329V — POAG 47 25/25 ND 2.59/2.59
99195 R368H — NTG 56 21/21 I/I 2.68/3.55
11806 R368H — POAG 44 32/33 ND 3.6/3.8
Maximum IOP at time of diagnosis (Goldmann applanation tonometry); optic disc atrophy according to Jonas (from normal 0, moderate
cupping I, notching of the neuroretinal rim (NRR) II–III, temporal NRR loss IV, to complete atrophy V); optic disc area of left and right eye,
respectively, measured with planimetry or laser scanning tomography (HRT; Heidelberg Engineering, Heidelberg, Germany).
TABLE 3. Combined Analysis of Different Studies on Functionally Validated CYP1B1 Mutations in Patients with POAG
Study Groups Ancestry Patients Mutations Undetermined Controls Mutations
Melki et al.14 French 236 6 1 47 1
Acharya et al.15 Indian 200 2 6 100 0
Lopez-Garrido, et al.16 Spanish 119 7 4 92 0
Kumar et al.28 Indian 251 10 3 100 2
Chakrabarti et al.31 Indian 224 11 6 200 0
This study German 399 13 — 376 1
Total 1429 49 20 915 4
Percentage 100 3.4 1.4 — 0.4
Data from larger studies that reported CYP1B1 mutation frequencies in patients with POAG was reanalyzed based on updated functional
validation of mutations (Refs. 18,19,33, and this study). Undetermined refers to mutations, whose functional relevance has not been determined as
yet. Overall, 1429 patients of different ancestry were investigated. In each study and overall, patients were more likely to carry a functionally
impaired mutation with an associated OR  3.85 (95% CI  2.21–6.70), P  2.3  107 (two-tailed Fisher’s exact test).
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effects of many variants found, thus presenting an unequivocal
classification of them. In these aspects, the CYP1B1 mutation
rate in our POAG patient cohort was significantly increased
over that expected (P  0.0018, Fisher’s exact test). Further,
our reanalysis of the previous studies about CYP1B1 associa-
tion to POAG14–16,28,31 takes into account the functional clas-
sification of the CYP1B1 mutations, determined in this and
other works,18,19,29,33 and combined the number of all patient
groups screened together against all control subjects. As ex-
pected we observed an increase in significance (P  2.3 
107; two-tailed Fisher’s exact test), thus strengthening the
association of functionally characterized CYP1B1 mutations in
POAG.
Our results emphasize once more both the importance of
functional classification of variants, especially in highly poly-
morphic genes, and the large number of patients necessary to
achieve sufficient power when assessing the contribution of a
gene to the pathogenesis of a complex disease such as POAG.
Previous data7,9 support the hypothesis that POAG is char-
acterized by a high locus and allelic heterogeneity with many
different rare variants in numerous genes. In fact, rare muta-
tions with low frequencies have also been reported for the
other known glaucoma genes such as MYOC34 and WDR36.22
Taken together, these observations suggest that POAG belongs
to the same category of traits under the frequent disease–rare
variant hypothesis, such as epilepsy35 and macular degenera-
tion.36 Characteristics of these diseases are rare, with highly
penetrant variants found in numerous genes. Some of these
variants are familiar, but most occur sporadically.37,38 This
sporadic occurrence could explain the so far elusive quest to
identify more glaucoma genes and has important conse-
quences for designing future studies aimed at unraveling the
molecular basis of this devastating disease.
To our knowledge, this is the largest association study
linking POAG and rare CYP1B1 variants to date and the first to
systematically classify variants based on relative enzymatic ac-
tivity. Our study and the reanalysis of previous studies supports
the hypothesis that CYP1B1 has a broader significance for
glaucoma pathogenesis than initially thought, ranging from a
causal effect in autosomal recessive PCG and other anterior
segment dysgenesis disorders, to a risk factor in POAG.
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APPENDIX
URLs of Data Sources
National Center for Biotechnology Information (NCBI), Be-
thesda, MD; http://www.ncbi.nlm.nih.gov/
Online Mendelian Inheritance in Man (OMIM), NCBI; http://
www.ncbi.nlm.nih.gov/entrez/query.fcgi?dbOMIM
Primer3 software, Whitehead Institute, Massachusetts Insti-
tute of Technology, Cambridge, MA; http://frodo.wi.mit.edu/
primer3/
Genome Browser of the University of California Santa Cruz
(UCSC), Santa Cruz, CA; http://genome.ucsc.edu/cgi-bin/
hgTracks (reference sequences used: NT_ 022184 and
NM_000104)
Swiss-Prot/TrEMBL Database, Sanger Centre, Hinxton, UK;
http://www.sanger.ac.uk/
Expert Protein Analysis System (ExPasy) proteomic server,
Swiss Institute of Bioinformatics, Geneva, Switzerland; http://
www.expasy.org (Reference sequence Q_Human)
ClustalW, European Bioinformatics Institute, European Mo-
lecular Biology Laboratory, Heidelberg, Germany; http://www.
ebi.ac.uk/clustalw/
Calculator for Odds Ratios and Confidence Intervals, written by
David J. R. Hutcheon; http://www.hutchon.net/ConfidOR.htm
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